List view / Grid view

Praluent (alirocumab)



NICE says ‘no’ to alirocumab in draft guidance

8 February 2016 | By Victoria White

NICE was concerned that alirocumab had not been compared with the combination therapy of ezetimibe plus a statin and that trials of the drug were not able to provide robust information on cardiovascular outcomes...


Sanofi and Regeneron announce new results from six Phase 3 trials showing that alirocumab significantly reduced LDL cholesterol

19 November 2014 | By Sanofi / Regeneron Pharmaceuticals

Sanofi and Regeneron Pharmaceuticals, Inc. today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Alirocumab is an investigational fully human monoclonal antibody targeting the protein PCSK9 (proprotein convertase subtilisin/kexin type 9) that is being evaluated…